ArticleThe FEBS journal2026
RAB4A acts as a negative feedback regulator of extracellular vesicle secretion during TGF-β signaling.
Article in The FEBS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- SNAI1 ablation alters integrin-mediated adhesion and endocytic fate.Cell death & disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Extracellular vesicles (EVs) secreted by cancer cells actively modulate the tumor microenvironment, thereby promoting cancer progression. Transforming growth factor-β (TGF-β) signaling has been implicated in the regulation of EV biogenesis, yet the molecular mechanisms underlying this process have only recently begun to emerge. In this study, we investigated TGF-β-responsive mediators that regulate EV release in lung, breast, and ovarian carcinoma cells by modulating the expression and activity of genes associated with EV biogenesis, including components of the ESCRT machinery, tetraspanins, and Rab GTPases. We found that TGF-β selectively enhances the mRNA expression of PDCD6IP (ALIX), CD81, ARF6, and RAB4A in a cell type-specific manner. R-SMAD silencing had clear negative effects on the regulation of ALIX or RAB4A, whereas AKT kinase inhibition suppressed the induction of ALIX and CD81. Additionally, TGF-β stimulation increased ALIX S-palmitoylation, consistent with enhanced ALIX-TSG101 complex formation on vesicular membranes. However, knockdown of ALIX or CD81 did not impair TGF-β-induced EV secretion. On the contrary, TGF-β-induced upregulation of RAB4A expression is functionally unique because RAB4A facilitates fast endosomal recycling, a process that limits EV release. Accordingly, silencing RAB4A significantly increased the fusion of multivesicular bodies with the plasma membrane followed by EV secretion, suggesting that TGF-β-induced RAB4A acts as a negative feedback regulator of EV release. Our findings reveal a novel mechanism by which RAB4A modulates TGF-β-driven EV production by cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.